COMPARISON
Bacitracin vs Daptomycin
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Bacitracin is authorised or registered in 8 and Daptomycin in 10 of the 10 registers read. Bacitracin: No trial states a phase. Daptomycin: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Bacitracin | Daptomycin | |
|---|---|---|
| Registered trials differs | 53 clinicaltrials.gov · 2026-10-03 | 132 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, not an approval: health and .beyond Triple Antibiotic openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Daptomycin openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for bacitracin | 2006-01-19 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for bacitracin | J01XX09 ema · 2026-10-03 |
LEGAL STATUS
Approval in each country read
| Country | Bacitracin | Daptomycin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.